ASRS 2018

    Dr. Charles Wykoff shares the 6-month preliminary findings of the PANORMA study in this interview from ASRS 2018. This study was a prospective, multicenter, double-masked, randomized phase 3 trial evaluating aflibercept treatment for moderate and severe nonproliferative diabetic retinopathy (NPDR). Patients were randomized into 1 of 2 different aflibercept treatment groups or into the sham control group. The study met its primary outcome at 24 weeks, with more than 58% of patients in the aflibercept arms improving by 2 steps or more in DR severity scores, compared with just 6% of patients the sham arm. The study will continue to evaluate patients over 2 years.

    Relevant Financial Disclosures: Dr. Wykoff is a consultant for and receives grant support and lecture fees from Regeneron Pharmaceuticals.